Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

NCNA - NuCana plc - ADR


IEX Last Trade
3.49
-4.240   -121.490%

Share volume: 438,395
Last Updated: Fri 30 Aug 2024 08:48:11 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$7.73
-4.24
-54.85%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
22%
Profitability 18%
Dept financing 2%
Liquidity 50%
Performance 25%
Company vs Stock growth
vs
Performance
5 Days
-48.38%
1 Month
6.77%
3 Months
1.10%
6 Months
-55.41%
1 Year
-80.71%
2 Year
-90.17%
Key data
Stock price
$3.49
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$2.53 - $20.26
52 WEEK CHANGE
-$0.77
MARKET CAP 
9.673 M
YIELD 
N/A
SHARES OUTSTANDING 
2.643 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$118,908
AVERAGE 30 VOLUME 
$100,379
Company detail
CEO: Hugh Griffith
Region: US
Website: http://www.nucana.com/
Employees: 31
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

nucana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our phosphoramidate chemistry technology to transform some of the most widely prescribed chemotherapy agents into more effective and safer medicines. while these conventional agents remain part of the standard of care for the treatment of many solid tumours, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. utilising our proprietary protide technology, we are developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.

Recent news